2011-11-11T13:48:55-06:00 2010-12-31 ARGY WILTSE & ROBINSON PC 8405 GREENSBORO DRIVE 7TH FLOOR MCLEAN VA 22102 990 2010-01-01 522044704 Aeras Global TB Vaccine Foundation AERA 3015472900 1405 RESEARCH BLVD ROCKVILLE MD 20850 james connolly 2011-11-10 DAVID J TRIMNER 7038930600 2010 2016-03-07 17:11:31Z JAMES CONNOLLY 1405 RESEARCH BLVD ROCKVILLE MD 20850 61712231 false X WWW.AERAS.ORG X 1997 DC A NON-PROFIT PRODUCT DEVELOPMENT ORG DEDICATED TO THE DEVELOPMENT OF THE EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. 12 10 159 0 4617516 -274083 48464880 40042948 820049 4806253 265737 84759 0 0 49550666 44933960 863852 918117 0 0 16958357 15855649 0 0 0 39451974 34821881 57274183 51595647 -7723517 -6661687 51275187 46339041 9073270 9686830 42201917 36652211 X AERAS IS A NON-PROFIT PRODUCT DEVElOPMENT ORGANIZATION DEDICATED TO THE DEVELOPMENT OF EFFECTIVE TUBERCULOSIS (TB) VACCINES AND BIOLOGICS TO PREVENT TB ACROSS ALL AGE GROUPS IN AN AFFORDABLE AND SUSTAINABLE MANNER. AERAS UTILIZES ITS BROAD CAPABILITIES AND TECHNOLOGIES IN COLLABORATION WITH NUMEROUS PARTNERS AND STAkEHOLDERS TO SUPPORT THE DEVELOPMENT OF VACCINES AND OTHER BIOPHARMACEUTICALS TO ADDRESS TB AND OTHER SIGNIFICANT PUBLIC HEALTH NEEDS OF UNDERSERVED POPULATIONS. IN THE PURSUIT OF OUR MISSION, WE ARE GUIDED BY OUR CORE VALUES. THESE CORE VALUES EXPRESS OUR ASPIRATIONS AND THE BEHAVIORS WE WANT TO EXHIBIT AND MODEL. THEY SHAPE THE CULTURE AND CHARACTER OF AERAS AND INFORM ALL OF OUR DECISIONS AND ACTIONS. false false 12428386 Discovery/Preclinical - Aeras develops a range of recombinant Bacille Calmette-Gurin (rBCG) variations and explores novel approaches to enhance the effectiveness of new TB vaccines to advance the development of a better BCG vaccine and effective prime-boost regimens. In pre-clinical development, Aeras assesses and evaluates TB vaccine candidates to determine whether they have the characteristics needed to move forward to the next phase of development. Key elements include evaluation of safety, immunogenicity and the protection the candidates provide in animal models. An independent panel of vaccine experts evaluate all relevant pre-clinical data before a candidate is approved for entry into Phase I trials. 16565241 Clinical - Aeras and its research partners have transformed the TB vaccine clinical landscape by moving several vaccine candidates into advanced stages of clinical trials. Among the many clinical trials sponsored by Aeras, six vaccine candidates in its portfolio, two of which are designed as "booster" vaccines, are currently undergoing testing in phase IIb proof-of-concept clinical trials. The improved recombinant Bacille Calmette-Gurin (rBCG) vaccine entered a safety trial in 2010. 12131017 Tech Operations - Vaccine manufacturing facility located at Aeras headquarters designed to manufacture internally developed vaccine candidates based on a range of technology platforms capabilities in bacterial, viral and protein vaccines. Aeras has cGMP-compliant, end-to-end equipment and operating capabilities that meet both US FDA and European EMEA standards. Process development and manufacturing capabilities support translation from research to clinical development, including manufacturing of clinical trial materials for Aeras-sponsored trials. THE Facility is also used in collaboration with external vaccine partners and contract product development services clients. 3576988 188737 44701632 true true false false false false false false false false true false false false true true false true false true true true false false false false false false false true false false false false false false false false false false false false false true true true false false true 65 0 159 true true true true SF false false false false false false false false X 12 10 false false false false false false false true true false false true true true true true true true true false MD X X DONNA D'AMATO 3015472923 1405 RESEARCH BLVD STE 300 ROCKVILLE MD 20850 X R GORDON DOUGLAS JR 40.0 X X 210000 0 0 ANN M GINSBERG MD PHD 1.0 X 0 0 0 MICHEL GRECO MS MBA 1.0 X 0 0 0 PETER BARTON HUTT LLM 1.0 X 0 0 0 DAVID MCMURRAY MS PHD 1.0 X 0 0 0 PHILIP K RUSSELL MD 1.0 X 0 0 0 VIJAY SAMANT MS MBA 1.0 X 0 0 0 DOUGLAS B YOUNG PHD 1.0 X 0 0 0 HOOSEN COOVADIA MD 1.0 X 0 0 0 JERALD SADOOF 40.0 X X 468035 0 5083 REGINA RABINOVICH MD MPH 1.0 X 0 0 0 K Vijay Raghavan PHD 1.0 X 0 0 0 JAMES CONNOLLY 40.0 X X 174745 0 2529 WALTER KALLAUR 40.0 X 268162 0 19774 JOHN BRUCE MCLAIN 40.0 X 281707 0 30597 CALVIN HARRIS JR 40.0 X 167910 0 17410 THOMAS EVANS 40.0 X 101042 0 5244 LEWELLYS BARKER 40.0 X 225825 0 18823 ERIC TSAO 40.0 X 225135 0 31445 JOHN FULKERSON 40.0 X 203159 0 8413 MICHAEL BRENNAN 40.0 X 205129 0 22572 ROBERT WALKER 40.0 X 276592 0 20828 DONATA SIZEMORE 40.0 X 198607 0 19843 MARGARET WILLINGHAM 40.0 X 203172 0 14889 MARGARET GOETZ 40.0 X 200662 0 14992 BARBARA SHEPHERD 40.0 X 171177 0 16570 SADRITIN ISHMUKAHMEDOV 40.0 X 167422 0 20439 DWAYNE WILSON 40.0 X 166173 0 15463 JAMES ZHOU 40.0 X 162654 0 25585 4077308 0 310499 41 false true false UNIVERSITY OF CAPE TOWN RONDEBOSCH CAPETOWN 0 SF 7700 VACCINE DEV/RESEARCH 4652524 ALEXANDRIA REAL ESTATE 385 E COLORADO AVENUE STE 299 PASADENA CA 91101 REAL ESTATE/RENTAL 3538026 BIOMEDCIAL PRIMATE RESEARCH CENTRE PO BOX 3306 GH RIJWSWJK 0 NL 2280 VACCINE DEV/RESEARCH 1615968 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX NY 10461 VACCINE DEV/RESEARCH 811782 TRICLINIUM CLINIC RESEARCH SERVICES PO BOX 55132 NORTHLANDS 0 SF 2116 VACCINE DEV/RESEARCH 645428 39 7717410 32325538 40042948 VACCINE MANUFACTURING 541900 4617516 0 4617516 0 GLOBAL FORUMS REVENUE 900099 188737 188737 0 0 4806253 109930 109930 0 0 16745000 8100 16772788 5483 -27788 2617 -25171 -25171 0 0 0 0 44933960 188737 4617516 84759 0 0 918117 918117 0 3426668 2841647 585021 0 0 9710062 8052302 1657760 0 517907 457199 60708 0 1287606 1119561 168045 0 913406 789338 124068 0 0 740261 197565 542696 0 122538 32704 89834 0 0 0 0 486746 129905 356841 0 0 534514 328444 206070 0 0 0 3925919 3075652 850267 0 733425 544934 188491 0 0 0 0 0 4771662 4426592 345070 0 371583 161951 209632 0 CONTRACT SERVICES 13828342 13610684 217658 0 COLLABORATION AGREEMENTS 4402635 3474518 928117 0 LAB SUPPLIES AND MATERIALS 3129311 3129311 0 0 REPAIRS 714483 650112 64371 0 BAD DEBT EXPENSE 502367 502367 0 0 558095 258729 299366 0 51595647 44701632 6894015 0 0 300 24857427 16406529 1805469 4011 170461 1989673 554069 273598 35209576 15789660 23677605 19419916 0 7994440 210156 250574 51275187 46339041 6890833 6365818 390412 1518484 1792025 1802528 9073270 9686830 X 21903845 16326256 20298072 20325955 42201917 36652211 51275187 46339041 X -6661687 1111981 X false true true X false X JOHNs HOPKINS HOSPITAL BALTIMORE MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 18124057 5979346 12144711 157915 66123 91792 14203560 7825192 6378368 2724043 1918999 805044 19419916 0 DEFERRED RENT 1802528 1802528 44933960 51595647 -6661687 -2976 -229566 -232542 -6894229 44706034 -2976 -222333 -225309 44931343 2617 2617 44933960 51600263 4616 4616 51595647 51595647 CHANGE IN NET ASSETS - OTHER FORM 990, SCHEDULE D, PART XI, LINE 8 FOREIGN CURRENCY LOSS: (228,332) NET INCOME OF AFFILIATE: (1,234) RECONCILIATION OF REVENUE OTHER ADJSUTMENTS FORM 990, SCHEDULE D, PART XII, LINE 2D AND LINE 4B PART XII, LINE 2D, Other INVESTESTMENT INCOME OF AFFILIATE: 5,999 Foreign Currency Loss: (228,332) PART XII, LINE 4B, OTHER GAIN (LOSS) ON DISPOSALS: 2,617 RECONCILIATION OF EXPENSES OTHER ADJUSTMENTS FORM 990, SCHEDULE D, PART XIII, LINE 2D PART XIII, LINE 2D EXPENSES OF AFFILIATE: 7,233 GAIN/LOSS ON DISPOSALS: (2,617) FIN 48 FOOTNOTE FORM 990, SCHEDULE D, PART X, LINE 2 IN ACCORDANCE WITH AUTHORITATIVE GUIDANCE ISSUED BY THE FASB, THE ORGANIZATION RECOGNIZES TAX LIABILITIES WHEN, DESPITE MANAGEMENT'S BELIEF THAT TAX RETURN POSITIONS ARE SUPPORTABLE, THE ORGANIZATION BELIEVES THAT CERTAIN POSITIONS MAY NOT BE FULLY SUSTAINED UPON REVIEW BY TAX AUTHORITIES. BENEFITS FROM TAX POSITIONS ARE MEASURED AT THE LARGEST AMOUNT OF BENEFIT THAT IS GREATER THAN 50% LIKELY OF BEING REALIZED UPON SETTLEMENT. TO THE EXTENT THAT THE FINAL TAX OUTCOME OF THESE MATTERS IS DIFFERENT THAN THE AMOUNTS RECORDED, SUCH DIFFERENCES IMPACT INCOME TAX EXPENSE IN THE PERIOD IN WHICH SUCH DETERMINATION IS MADE. INTEREST AND PENALTIES, IF ANY, RELATED TO ACCRUED LIABILITIES FOR POTENTIAL TAX ASSESSMENTS ARE INCLUDED IN INCOME TAX EXPENSE. WITH FEW EXCEPTIONS, THE ORGANIZATION IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS BY THE U.S. FEDERAL, STATE OR LOCAL TAX AUTHORITIES FOR YEARS ENDED DECEMBER 31, 2006 AND PRIOR. MANAGEMENT HAS EVALUATED THE ORGANIZATION'S TAX POSITIONS AND HAS CONCLUDED THAT THE ORGANIZATION HAS TAKEN NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE ADJUSTMENT TO THE CONSOLIDATED FINANCIAL STATEMENTS TO COMPLY WITH THE PROVISIONS OF THIS GUIDANCE. true Sub-Saharan Africa 1 9 Program Services CLINICAL SITE 918117 1 9 1 9 918117 918117 Sub-Saharan Africa SEE PART V 918117 WIRE CASH 1 0 false false true false false false MONITORING THE USE OF GRANTS FORM 990, SCHEDULE F, PART I, LINE 2 Aeras receives a request for support. Senior management reviews the request through due diligence and criteria approved by the Board and implemented by management. For example, the grantee must be a charity either under US law or under local law. Aeras may request governance documents from the organization, IRS determination letter (or local equivalent) indicating it is a charity, lists of executive staff and board members, and financial statements of the requestor. Upon management approval, funds are sent to the requesting organization. Copies of the request and payment are maintained at Aeras. PURPOSE OF GRANT FORM 990, SCHEDULE F, PART II, COLUMN (D) THE PURPOSE OF THE GRANT IS TO SUPPORT THE MISSION OF THE ORGANIZATION, TO DEVELOP, TEST, CHARACTERIZE, LICENSE, MANUFACTURE AND DISTRIBUTE NEW TB VACCINE. X X true true X X X X true false false false false false false false false R GORDON DOUGLAS JR 0 0 0 0 210000 0 0 0 0 0 210000 0 0 0 JERALD SADOOF 70140 0 0 0 397895 0 2827 0 2256 0 473118 0 0 0 WALTER KALLAUR 213730 0 54432 0 0 0 11555 0 8219 0 287936 0 0 0 LEWELLYS BARKER 225825 0 0 0 0 0 8216 0 10607 0 244648 0 0 0 ERIC TSAO 225135 0 0 0 0 0 13634 0 17811 0 256580 0 0 0 JOHN BRUCE MCLAIN 281707 0 0 0 0 0 14700 0 15897 0 312304 0 0 0 JOHN FULKERSON 203159 0 0 0 0 0 0 0 8413 0 211572 0 0 0 CALVIN HARRIS JR 167910 0 0 0 0 0 10080 0 7330 0 185320 0 0 0 MICHAEL BRENNAN 204086 0 1043 0 0 0 12179 0 10393 0 227701 0 0 0 JAMES CONNOLLY 174745 0 0 0 0 0 1696 0 833 0 177274 0 0 0 ROBERT WALKER 276592 0 0 0 0 0 14700 0 6128 0 297420 0 0 0 DONATA SIZEMORE 198607 0 0 0 0 0 11809 0 8034 0 218450 0 0 0 MARGARET GOETZ 200662 0 0 0 0 0 6123 0 8869 0 215654 0 0 0 BARBARA SHEPHERD 171177 0 0 0 0 0 11809 0 4761 0 187747 0 0 0 SADRITIN ISHMUKAHMEDOV 167422 0 0 0 0 0 3900 0 16539 0 187861 0 0 0 DWAYNE WILSON 166173 0 0 0 0 0 9883 0 5580 0 181636 0 0 0 JAMES ZHOU 162654 0 0 0 0 0 10148 0 15437 0 188239 0 0 0 MARGARET WILLINGHAM 203172 0 0 0 0 0 12095 0 2794 0 218061 0 0 0 SEVERANCE PAYMENT FORM 990, SCHEDULE J, LINE 4A DURING THE TAX YEAR MR. JERALD SADOFF RECEIVED A SEVERANCE PAYMENT IN THE AMOUNT OF $397,895. FIRST-CLASS OR CHARTER TRAVEL FORM 990, SCHEDULE J, LINE 1A FIRST CLASS TRAVEL IS GENERALLY ONLY AUTHORIZED FOR INTERNATIONAL TRAVEL OR TRIPS OVER A CERTIAN DISTANCE. FORM 990 REVIEW PROCESS form 990, PART VI, LINE 11B A draft version of the Form 990 is shared with the Board of Directors of Aeras and once approved it is filed with the IRS. CONFLICT OF INTEREST POLICY FORM 990, PART VI, LINE 12 Aeras' policy is written to protect the Foundation's interest when it is contemplating entering into a transaction or arrangement that might benefit the private interest of directors, committee members, officers, employees and retained consultants of the Foundation. In connection with any actual or possible conflicts of interest, an interested person must disclose the existence of his or her interest and all material facts to the directors and members of the committee with board-delegated powers considering the proposed transaction or arrangement. After disclosure of all material facts and discussion with the person, the person shall leave the board or committee meeting while their determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. DETERMINING COMPENSATION FORM 990, PART VI, LINE 15 Aeras has a Compensation Committee which determines the CEO compensation level based on his responsibilities, size of the organization, funding levels and organization objectives. Compensation is based on comparability data, is approved by independent Board members, and the process is documented in the Board minutes. Compensation for other officers is determined by the CEO, based on the officer's responsibilities, funding levels and organization objectives. compensation is based on comparability data and is shared with independent board members. AVAILABILITY OF OTHER DOCUMENTS FORM 990, PART VI, LINE 19 Governing documents, including Articles of Incorporation, Bylaws, Board minutes, Conflict of Interest policy and financial statements are available upon request. OTHER PROGRAM SERVICES FORM 990, PART III, LINE 4D Aeras also works to build relationships that support ITS goal to develop TB vaccines through collaboration at the global and regional levels with multi-lateral organizations such as the World Health Organizations, among other TB researchers and vaccine developers, as well as with donors, advocates and policymakers who can help raise awareness and support for this work. Aeras' Medical Affairs, Regulatory Affairs and External Affairs departments are critical to advancing these strategic partnerships to ensure success. OTHER CHANGES IN NET ASSETS OR FUND BALANCES FORM 990, PART XI, LINE 5 NET UNREALIZED GAINS (LOSSES) ON INVESTMENTS: $(2,975) FOREIGN CURRENCY LOSS: $(228,332) PRIOR PERIOD AUDIT ADJUSTMENT: $1,343,289 TOTAL ADJUSTMENT : $1,111,981 AERAS SOUTH AFRICA 1ST FL BELMONT SQ BELMONT RD RONDEBOSCH SF 7701 CLINICAL TR SF N/A N/A NA false true false false false false false false false false false false false false false false false false AERAS SOUTH AFRICA B 918117